Findings

What do systematic reviews say?

4 questions · 4 findings · 3 reviews · Gut

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 25%GRADE not reported 0 · 0%Very low 1 · 25%Low 2 · 50%Moderate 0 · 0%High 0 · 0%

Prebiotic vs placebo

Total adverse events · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)

The review found no eligible studies for this question.

1 finding from 1 review

Prebiotics for induction and maintenance of remission in ulcerative colitis 2024 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tacrolimus vs placebo

Total adverse events · adults with refractory, moderate‐to‐severe ulcerative colitis

Tacrolimus showed no clear difference in total adverse events compared with placebo (low certainty).

1 finding from 1 review

Tacrolimus (FK506) for induction of remission in corticosteroid‐refractory ulcerative colitis 2022 · Cochrane Headline outcomes only
RR 1.18 [0.91, 1.54]
3 studies · 148 participants
Low

Summary of findings table ‐ Stem Cell vs placebo or control

Total adverse events · Induction of Remission in Medically Refractory Crohn's Disease

It is very uncertain whether summary of findings table ‐ Stem Cell changes total Adverse Events compared with placebo or Control (very low certainty).

1 finding from 1 review

Stem cell transplantation for induction of remission in medically refractory Crohn’s disease 2022 · Cochrane Headline outcomes only
RR 0.99 [0.88, 1.13]
4 studies · 293 participants
Very low

Prebiotic vs placebo

Total adverse events (6 months) · people with histologically confirmed diagnosis of ulcerative colitis in remission

Prebiotics may leads to higher total adverse events (6 months) compared with placebo (low certainty).

1 finding from 1 review

Prebiotics for induction and maintenance of remission in ulcerative colitis 2024 · Cochrane Headline outcomes only
RR 1.68 [1.18, 2.4]
1 study · 89 participants
Low